Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

423

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

November 8, 2023

Study Completion Date

November 8, 2023

Conditions
Coronary Heart Disease (CHD)
Interventions
BIOLOGICAL

MEDI6570

MEDI6570

BIOLOGICAL

Placebo

Buffer

Trial Locations (84)

1133

Research Site, Budapest

1134

Research Site, Budapest

3168

Research Site, Clayton

4032

Research Site, Debrecen

5000

Research Site, Adelaide

5042

Research Site, Bedford Park

8000

Research Site, Székesfehérvár

14221

Research Site, Buffalo

15706

Research Site, Santiago de Compostela

20089

Research Site, Rozzano

20138

Research Site, Milan

22601

Research Site, Winchester

28040

Research Site, Madrid

28046

Research Site, Madrid

30033

Research Site, Decatur

30120

Research Site, El Palmar

32081

Research Site, Ponte Vedra

36312

Research Site, Pontevedra

36608

Research Site, Mobile

41009

Research Site, Seville

43126

Research Site, Parma

44124

Research Site, Cona

44710

Research Site, Canton

46002

Research Site, Liberec

47303

Research Site, Muncie

47374

Research Site, Richmond

48640

Research Site, Midland

50266

Research Site, West Des Moines

53792

Research Site, Madison

57701

Research Site, Rapid City

65212

Research Site, Columbia

90211

Research Site, Beverly Hills

90502

Research Site, Torrance

91324

Research Site, Northridge

91325

Research Site, Northridge

91723

Research Site, Covina

08901

Research Site, New Brunswick

WA6150

Research Site, Murdoch

WA 6000

Research Site, Perth

K1Y 4W7

Research Site, Ottawa

M5G 2C4

Research Site, Toronto

H1T 1C8

Research Site, Montreal

656 91

Research Site, Brno

500-05

Research Site, Hradec Králové

532 03

Research Site, Pardubice

305 99

Research Site, Plzen - Bory

150 06

Research Site, Prague

H-1122

Research Site, Budapest

670-0981

Research Site, Himeji-shi

816-0864

Research Site, Kasuga-shi

487-0016

Research Site, Kasugai-shi

802-8555

Research Site, Kitakyushu-shi

860-0008

Research Site, Kumamoto

606-8507

Research Site, Kyoto

271-0077

Research Site, Matsudo-Shi

861-4193

Research Site, Minamiku

880-0834

Research Site, Miyazaki

020-0066

Research Site, Morioka

558-8558

Research Site, Osaka

980-0873

Research Site, Sendai

1814 HB

Research Site, Alkmaar

7416 SE

Research Site, Deventer

6419 PC

Research Site, Heerlen

6525 GA

Research Site, Nijmegen

6532 SZ

Research Site, Nijmegen

5042AD

Research Site, Tilburg

3508 AB

Research Site, Utrecht

5912 BL

Research Site, Venlo

8025 AB

Research Site, Zwolle

15-276

Research Site, Bialystok

85-095

Research Site, Bydgoszcz

40-635

Research Site, Katowice

30-082

Research Site, Krakow

30-688

Research Site, Krakow

31-202

Research Site, Krakow

45-401

Research Site, Opole

50-556

Research Site, Wroclaw

08003

Research Site, Barcelona

08907

Research Site, Hospitalet de Llobregat(Barcel

HP21 8AL

Research Site, Aylesbury

EX2 5DW

Research Site, Exeter

TS4 3BW

Research Site, Middlesbrough

NE7 7DN

Research Site, Newcastle upon Tyne

M23 9LT

Research Site, Wythenshawe

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The TIMI Study Group

OTHER

lead

AstraZeneca

INDUSTRY